《半日总结》港股跌461点 科技券商股挫 中生制药跌逾7%
美国新申领失业救济人数上升，市场关注经济复苏脱轨。特朗普称中美贸易协议意义大减，美国大举搜捕与解放军有关连中国人，中国指令美国关闭驻成都美领事馆，中美关系紧张升温，中港股市受压。恒指低开222点後跌幅扩大，曾跌529点见24,733点，半日跌461点或1.8%，报24,801点；国指跌205点或2%，报10,119点。大市半日成交总额804.45亿元，沪港通南下交易半日录得净流出金额9,910万元人民币，深港通南下交易半日录得净流入金额24.06亿元人民币。
主要科网股受压，腾讯(00700.HK)跌4.6%报531.5元，阿里巴巴(09988.HK)跌2.4%报240.8元，美团点评(03690.HK)跌2.9%报193.3元，小米(01810.HK)跌3.8%报15.34元，京东(09618.HK)及网易(09999.HK)各跌3.2%及4.1%。
其余科网股方面，恒腾网络(00136.HK)及心动(02400.HK)各跌9.1%及8.2%，阿里健康(00241.HK)、阅文(00772.HK)、新东方在线(01797.HK)、众安在线(06060.HK)、微盟(02013.HK)及金山软件(03888.HK)各跌5.2%至7%。
手机相关股方面，鸿腾(06088.HK)挫7.8%，丘钛(01478.HK)及比亚迪电子(00285.HK)各跌4%及4.5%。电讯设备股中兴通讯(00763.HK)跌3.8%．，晶片股华虹半导体(01347.HK)及中芯(00981.HK)各跌6.3%及4%。
内地股市下滑，券商股捱沽，中金公司(03908.HK)、中信证券(06030.HK)、光大证券(06178.HK)及华泰证券(06886.HK)各跌逾6%。医药股受挫，中生制药(01177.HK)跌7.4%，威高(01066.HK)、信达生物(01801.HK)及药明生物(02269.HK)各跌5.4%至6.7%。汽车股比亚迪(01211.HK)亦跌6.2%。出口股创科(00669.HK)及敏华(01999.HK)各跌3.2%及7.7%，航空股国泰(00293.HK)跌4.7%。
军工股受追捧，中船防务(00317.HK)及中航科工(02357.HK)各升9.5%及5.1%。汽车股长城汽车(02333.HK)中绩胜预期获大行升目标价，股价逆市升7.9%。
其余蓝筹方面，汇控(00005.HK)跌1%报36.2元，港交所(00388.HK)跌3.5%报362.8元，友邦(01299.HK)跌1.2%报71.95元，建行(00939.HK)、中行(03988.HK)及中国平安(02318.HK)各跌1.5%，国寿(02628.HK)跌3.3%，中移动(00941.HK)则升0.9%报53.45元。地产股九仓置业(01997.HK)再跌逾5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
